Idera reports FDA hold lifted on dual TLR7/TLR9 antagonist study
This article was originally published in Scrip
Executive Summary
A day after Idera Pharmaceuticals' shares soared as high as 24.6% after German drug maker Merck KGaA returned the global rights to IMO-2055, a toll-like receptor 9 (TLR9) agonist under investigation to treat various cancers, the Cambridge, Massachusetts-based biotech said the US FDA lifted the hold on the company's Phase II trial for its dual TLR7/TLR9 antagonist IMO-3100.